KalVista Pharmaceuticals (KALV) Operating Income (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Operating Income of -$59.0 million in Q3 2025, down 7.23% quarter-over-quarter from -$55.0 million in Q2 2025, and down 33.46% year-over-year from -$88.7 million in Q3 2024.
KalVista Pharmaceuticals' Operating Income history runs 12 years deep, the most recent figure standing at -$59.0 million for Q3 2025.
- In Q3 2025, Operating Income fell 33.46% year-over-year to -$59.0 million; the TTM figure through Jul 2025 stood at -$204.1 million (down 31.17% YoY), while the FY2025 annual figure was -$188.0 million, down 33.86% from the prior year.
- Operating Income came in at -$59.0 million for Q3 2025 at KalVista Pharmaceuticals, down from -$55.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$12.7 million in Q1 2021 to a low of -$59.0 million in Q3 2025.
- A 5-year average of -$32.4 million and a median of -$28.0 million in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income climbed 0.53% in 2021 and slumped 110.82% in 2022, its largest moves.
- KalVista Pharmaceuticals' Operating Income stood at -$23.6 million in 2021, then declined by 9.66% to -$25.9 million in 2022, then declined by 14.92% to -$29.7 million in 2023, then plunged by 54.01% to -$45.8 million in 2024, then slipped by 28.81% to -$59.0 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$59.0 million, -$55.0 million, and -$45.8 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -59.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -59.01 Mn |
| Apr 30, 2025 | -55.03 Mn |
| Oct 31, 2024 | -45.81 Mn |
| Jul 31, 2024 | -44.22 Mn |
| Apr 30, 2024 | -48.46 Mn |
| Jan 31, 2024 | -33.15 Mn |
| Oct 31, 2023 | -29.75 Mn |
| Jul 31, 2023 | -29.09 Mn |
| Apr 30, 2023 | -31.73 Mn |
| Jan 31, 2023 | -26.95 Mn |
| Oct 31, 2022 | -25.88 Mn |
| Jul 31, 2022 | -26.32 Mn |
| Apr 30, 2022 | -26.81 Mn |
| Jan 31, 2022 | -26.68 Mn |
| Oct 31, 2021 | -23.60 Mn |
| Jul 31, 2021 | -19.52 Mn |
| Apr 30, 2021 | -18.04 Mn |
| Jan 31, 2021 | -12.66 Mn |
| Oct 31, 2020 | -12.78 Mn |
| Jul 31, 2020 | -14.44 Mn |
| Apr 30, 2020 | -8.96 Mn |
| Jan 31, 2020 | -12.72 Mn |
| Oct 31, 2019 | -9.29 Mn |
| Jul 31, 2019 | -9.56 Mn |
| Apr 30, 2019 | -11.26 Mn |
| Jan 31, 2019 | -6.66 Mn |
| Oct 31, 2018 | -4.89 Mn |
| Jul 31, 2018 | -7.01 Mn |
| Apr 30, 2018 | -2.97 Mn |
| Jan 31, 2018 | -4.35 Mn |
| Oct 31, 2017 | -5.94 Mn |
| Jul 31, 2017 | -5.45 Mn |
| Apr 30, 2017 | -5.09 Mn |
| Jan 31, 2017 | -8.12 Mn |
| Oct 31, 2016 | -4.03 Mn |
| Jul 31, 2016 | -5.12 Mn |
| Mar 31, 2016 | -6.53 Mn |
| Dec 31, 2015 | -5.57 Mn |
| Sep 30, 2015 | -4.90 Mn |
| Jun 30, 2015 | -5.67 Mn |
| Mar 31, 2015 | -4.90 Mn |
| Sep 30, 2014 | -3.57 Mn |
| Jun 30, 2014 | -2.44 Mn |
| Mar 31, 2014 | -1.86 Mn |